Wiskott-Aldrich misdiagnosis: avoiding costly ITP traps

The diagnostic problem arises when the presentation is treated as isolated ITP even though the platelet morphology, clinical history, or evolving immune features point toward an inborn error of immunity.

Wiskott-Aldrich syndrome (WAS) and its milder phenotype, X-linked thrombocytopenia (XLT), can initially resemble ITP because both conditions may produce severe thrombocytopenia and bleeding. The distinction is clinically important: WAS is an X-linked primary immunodeficiency caused by mutations in the WAS gene, and its management pathway extends well beyond platelet support or immunosuppressive treatment. A missed diagnosis can delay immunological assessment, infection prevention, genetic counselling, and timely evaluation for potentially curative hematopoietic stem cell transplantation.

Why Wiskott-Aldrich syndrome is mistaken for ITP

The overlap begins with the most visible part of the clinical presentation. A child has a low platelet count, bruising, mucosal bleeding, or petechiae, and the initial laboratory pattern may appear compatible with ITP. If the child has not yet developed significant infections or eczema, the immune component of WAS may remain clinically quiet.

This is particularly relevant in infants and young boys with XLT or an attenuated WAS phenotype. The classic triad of WAS includes:

• microthrombocytopenia, meaning a low platelet count accompanied by unusually small platelets;
• eczema, often beginning early in life and varying in severity;
• recurrent bacterial, viral, or fungal infections reflecting combined T- and B-cell dysfunction.

However, not every child shows the complete triad at presentation. Eczema can be absent or mild. Infections may not yet have accumulated into a recognizable pattern. Some children are therefore managed for presumed ITP before the broader immune phenotype becomes apparent.

The inheritance pattern should also shape clinical reasoning. WAS is an X-linked recessive disorder caused by pathogenic variants in the WAS gene on chromosome Xp11.22–Xp11.23. The gene encodes WAS protein, or WASp, a 502-amino-acid protein involved in cytoskeletal organization and immune-cell function. Because of the X-linked mechanism, classic disease predominantly affects males, although the clinical picture can vary considerably according to the specific variant and residual protein function.

ITP, by contrast, is an immune-mediated platelet disorder in which thrombocytopenia is generally the central abnormality. The child may have bleeding manifestations, but the platelet size is not typically characterized by the strikingly small platelets associated with classic WAS.

In a boy with thrombocytopenia, the platelet count tells us how many platelets are present; the mean platelet volume helps us ask what kind of disorder may be producing them.

That distinction is easy to miss when the clinical pathway is driven by the platelet count alone.

The platelet clue: why MPV matters

Mean platelet volume (MPV) is one of the most useful early clues in the differential diagnosis of WAS versus ITP. In classic WAS, platelets are characteristically small. Reported MPV values may be below approximately 5.0–7.0 fL, although laboratory methods, reference ranges, and disease variants affect interpretation. A typical reference range in many laboratories is roughly 6.5–11 fL, but the local laboratory interval should always be used when reviewing a result.

In ITP, platelets are more often normal in size or enlarged, reflecting increased release of young platelets from the bone marrow. This creates a practical contrast:

MPV is not a stand-alone diagnostic test. Platelet size can be distorted by sample handling, analyzer limitations, platelet clumping, or inadequate recognition of very small platelets on an automated count. For that reason, a persistently low MPV should prompt review of the peripheral blood smear and discussion with a pediatric hematologist or clinical immunologist rather than an immediate conclusion.

We also should not overstate the rule. Microthrombocytopenia is a hallmark of classic WAS, but rare atypical cases may have less characteristic platelet indices. A normal MPV does not automatically exclude every WAS-related disorder, particularly when the clinical history contains other warning signs. Conversely, a low MPV is a reason to investigate, not proof that a child has WAS.

The blood smear is more than a formality

The peripheral smear can help determine whether the automated indices reflect the child’s actual platelet morphology. It may also reveal additional features relevant to the differential diagnosis, although no single smear finding replaces molecular confirmation.

When a child has suspected ITP but the platelet volume is unexpectedly low, we should review:

• whether the platelet size is consistently small across samples;
• whether the automated platelet count may be affected by clumping or analyzer limitations;
• whether there are abnormalities in white-cell morphology or other blood-cell lines;
• whether the thrombocytopenia is isolated or accompanied by anemia or leukopenia;
• whether the clinical history includes eczema, recurrent infections, persistent viral illnesses, or unusual inflammatory complications.

This is the point at which a presumed isolated platelet disorder becomes an immune phenotype requiring a wider assessment.

What should trigger a WAS evaluation?

The decision to investigate Wiskott-Aldrich syndrome should be based on the whole clinical presentation, not on one laboratory value. The following combination deserves particular attention in a male child:

1. Thrombocytopenia with low MPV.

A reduced platelet count accompanied by unusually small platelets is the strongest early laboratory signal. The result should be confirmed and interpreted alongside a smear and the local laboratory reference range.

2. Bleeding that seems disproportionate or persistent.

Petechiae, easy bruising, epistaxis, gum bleeding, or gastrointestinal bleeding may be the first reason for medical review. Severity and pattern matter, particularly when thrombocytopenia does not follow the expected course for ITP.

3. Eczema or chronic inflammatory skin disease.

Eczema may be prominent in classic WAS, but an absent or modest rash does not exclude an attenuated phenotype. Recurrent skin infections or difficult-to-control dermatitis can add weight to the suspicion.

4. Recurrent, severe, or unusual infections.

Repeated bacterial infections, persistent viral infections, invasive fungal disease, or infections requiring unusually intensive treatment suggest that the problem may involve more than platelet destruction.

5. Poor or incomplete response to standard ITP therapy.

Intravenous immunoglobulin, corticosteroids, or thrombopoietin receptor agonists may be used in ITP, but they do not correct a WAS gene mutation or restore the underlying immune-cell defect. Failure to respond, rapid relapse, or repeated treatment dependence should lead to diagnostic reassessment rather than an automatic escalation of the same strategy.

6. A relevant family history.

Male relatives with unexplained thrombocytopenia, severe infections, eczema, early bleeding, or an established diagnosis of WAS or XLT can provide an important inheritance clue. The absence of such a history does not rule out the disorder, because new pathogenic variants can occur and family histories may be incomplete.

7. Autoimmune or inflammatory complications.

WAS can involve immune dysregulation in addition to infection susceptibility and bleeding. A child with thrombocytopenia plus other immune-mediated or inflammatory findings may need a broader inborn-errors-of-immunity assessment.

The most useful clinical question is not simply whether the child has responded to an ITP treatment. It is whether the complete pattern still makes isolated ITP the most coherent explanation.

When the diagnosis is being held together only by the platelet count, the management pathway is already too narrow.

The role of WAS gene mutation testing

Definitive confirmation requires molecular testing of the WAS gene, usually through sequencing and, when needed, additional methods that can identify larger deletions or duplications not detected by a basic sequencing approach. The precise testing strategy depends on the laboratory and the child’s phenotype.

Genetic testing is especially important because WAS and XLT exist on a clinical spectrum. Some variants cause classic disease with significant immune dysfunction, eczema, and bleeding. Others preserve more WASp function and produce predominantly thrombocytopenia with fewer infections or less severe eczema. The result is not merely a label: it helps determine prognosis, family evaluation, donor planning, and the urgency of specialist management.

A practical diagnostic pathway generally includes:

• repeat complete blood count with platelet indices;
• peripheral blood smear review;
• detailed history of bleeding, infections, eczema, inflammatory symptoms, and treatment response;
• assessment of immunoglobulins and lymphocyte populations as clinically indicated;
• WASp expression or functional studies where available and appropriate;
• WAS gene sequencing and interpretation by a qualified genetics or immunology team;
• evaluation of relatives when a pathogenic variant is identified.

The absence of a previously affected relative should not be used as reassurance when the phenotype is suggestive. Likewise, a genetic result must be interpreted in context. Variant classification can be complex, and a finding of uncertain significance does not automatically establish or exclude the diagnosis.

Why treatment response can mislead

ITP therapies are designed to reduce immune-mediated platelet destruction or increase platelet production. They may improve the platelet count in a child whose diagnosis is truly ITP. In WAS, however, a temporary rise in platelets does not resolve the genetic and immunological disorder.

A child with WAS may receive IVIG or corticosteroids and show a partial or transient improvement. That response can reinforce the initial diagnosis even though it is not specific to ITP. Similarly, thrombopoietin receptor agonists may alter platelet production without addressing susceptibility to infection, eczema, immune dysregulation, or the long-term risk profile associated with WAS.

The practical danger is diagnostic inertia: each new bleeding episode is interpreted as another ITP flare, and the child receives another course of the same treatment. Meanwhile, the opportunity for early immunology referral, family testing, infection prevention, and definitive treatment planning may be lost.

This does not mean that all treatment given before the diagnosis is inappropriate. Bleeding must be managed according to its severity, and urgent care may be necessary. The point is that supportive or platelet-directed treatment should not substitute for aetiological diagnosis when the clinical presentation is atypical.

From diagnosis to management: changing the pathway

Once WAS or XLT is suspected, care should move into a coordinated pediatric immunology and hematology pathway. The exact plan depends on the phenotype, genotype, infection history, platelet burden, bleeding risk, immune function, and available donor options.

Immediate clinical priorities

The first stage is to define the child’s current risks:

• How severe and frequent is the bleeding?
• Are there active or recurrent infections?
• Is eczema complicated by bacterial or viral infection?
• Are immunoglobulin levels and lymphocyte profiles abnormal?
• Are there signs of autoimmunity or systemic inflammation?
• Has the child received blood products or therapies that affect transplant planning?
• Are vaccinations and infection exposures being reviewed by an immunology team?

Children with suspected or confirmed immune deficiency should receive individualized vaccination guidance. Live vaccines may require particular caution depending on immune function and the specialist assessment. Families also need a clear plan for fever, respiratory symptoms, skin infections, and possible exposure to serious viral illness.

Definitive treatment and HSCT

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the primary curative treatment option for WAS. It can replace the abnormal hematopoietic system with donor-derived cells capable of producing functional immune cells and platelets.

The timing and suitability of HSCT are individualized. Disease severity, age, donor match, active infection, organ health, bleeding complications, and transplant-center experience all influence the decision. In children transplanted before the age of two with an HLA-matched donor, reported survival exceeds 90%, although this figure should not be treated as a personal prediction for every child or center.

Early diagnosis matters because transplant planning is more difficult when a child has accumulated severe infections, organ complications, or significant treatment-related risks. Earlier recognition also allows the team to evaluate relatives and potential donors in an orderly way rather than during an acute clinical deterioration.

For milder XLT phenotypes, the decision may be more nuanced. Some children require long-term monitoring rather than immediate transplantation, while others develop complications that change the risk-benefit assessment. The absence of severe infections in early childhood does not eliminate the need for specialist follow-up.

Gene therapy and clinical research

Gene-based approaches remain an important area of research for WAS, particularly for children who lack a suitable donor or whose clinical circumstances make conventional HSCT more complicated. These approaches are not interchangeable with established standard care, and eligibility, availability, and long-term evidence vary by study and treatment center.

Families considering a clinical trial should receive a careful explanation of:

• the trial’s phase and primary objectives;
• eligibility criteria and required baseline testing;
• conditioning treatment and associated risks;
• expected follow-up duration;
• how the investigational approach compares with available standard options;
• whether the study is accessible within the family’s healthcare system.

Research participation should complement, not delay, urgent management of bleeding, infection, or immune dysfunction.

Avoiding the common diagnostic traps

The most frequent errors do not usually come from ignoring WAS completely. They arise when a reasonable initial diagnosis is never revisited.

Trap 1: treating thrombocytopenia as the entire disease

A low platelet count is a finding, not a full diagnosis. If the child also has eczema, recurrent infections, unusual viral illness, or persistent treatment dependence, the immune system deserves assessment.

Trap 2: overlooking the MPV because the platelet count is dramatic

Severe thrombocytopenia naturally draws attention, but the size of the platelets may provide the more discriminating clue. A low MPV should be reviewed deliberately, especially in a male infant or child.

Trap 3: assuming that absent eczema excludes WAS

Eczema may be delayed, mild, intermittently documented, or overshadowed by bleeding. XLT may have little or no eczema. The clinical presentation can evolve over time.

Trap 4: interpreting treatment response as diagnostic confirmation

A temporary platelet rise after IVIG or corticosteroids does not prove ITP, and a lack of response does not by itself prove WAS. Treatment response must be integrated with morphology, infection history, immune testing, and genetic results.

Trap 5: waiting for severe infections before referring

The immune cascade in WAS can be clinically variable. Waiting until a child develops an invasive infection may postpone a diagnosis that could have been suspected from platelet morphology and family history much earlier.

Trap 6: treating a genetic diagnosis as the endpoint

A confirmed WAS gene mutation is the beginning of a structured care plan, not the conclusion. Families need an explanation of inheritance, testing for relatives, bleeding precautions, vaccination strategy, infection planning, reproductive counselling, and discussion of curative and supportive treatment options.

A practical consultation framework for families and clinicians

When a child has been labelled with ITP but the course is atypical, we can make the next consultation more productive by bringing together the information that is often scattered across hematology, emergency, dermatology, and primary-care records.

A useful summary includes:

• the lowest and most recent platelet counts;
• MPV values from more than one blood test, if available;
• whether a peripheral smear was reviewed;
• the age at first bruising, petechiae, or bleeding;
• details of eczema, skin infections, and persistent rashes;
• the number and type of significant infections;
• hospital admissions and antimicrobial treatments;
• responses and relapses after IVIG, corticosteroids, or other ITP-directed therapies;
• family history of male relatives with bleeding, thrombocytopenia, eczema, or recurrent infections;
• any previous immunological or genetic testing.

This information helps the specialist distinguish isolated thrombocytopenia from a broader inborn error of immunity. It also prevents the child’s clinical history from being reduced to a sequence of platelet counts and emergency treatments.

Parents should seek urgent medical advice for significant or uncontrolled bleeding, neurological symptoms, breathing difficulty, severe abdominal pain, or a high fever in a child known or suspected to have immune dysfunction. The appropriate response depends on the child’s individual plan, so families should ask the treating team in advance what symptoms require emergency assessment and which hospital should coordinate care.

Long-term outlook and quality of life

A diagnosis of WAS changes the clinical pathway, but it does not define a child’s potential quality of life. Outcomes depend on the disease phenotype, timing of recognition, complications before treatment, immune function, donor status, and access to experienced specialist care.

For children who undergo successful HSCT, immune and hematological function may improve substantially, although follow-up remains necessary. The transplant team will monitor immune reconstitution, infections, graft-related complications, organ health, growth, development, and late effects of treatment. Children managed without immediate transplantation also need continued surveillance because the balance between bleeding, infection, autoimmunity, and treatment burden can change over time.

The central lesson in Wiskott-Aldrich syndrome ITP misdiagnosis is not that every boy with thrombocytopenia has WAS. ITP remains an important diagnosis, and many children with thrombocytopenia will not have an inherited immunodeficiency. The lesson is that the diagnosis should remain open when the platelet morphology is unusual or when the clinical presentation extends beyond isolated bleeding.

A low MPV, recurrent infections, eczema, a relevant family history, or an incomplete response to standard ITP treatment should move the case toward immunological and genetic evaluation. With the correct diagnosis, families can replace repeated uncertainty with a defined management pathway: bleeding prevention, infection planning, specialist monitoring, genetic counselling, and timely consideration of curative treatment.

In pediatric immune disease, early recognition is not about attaching a rare label too quickly. It is about noticing when the first label no longer explains the whole child.